As of 3:59pm ET
| -0.06 / -3.73%|
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.
|Peter H. Nielsen||Chairman, President, CEO, CFO & Treasurer|
|Anthony Price||Director-Finance & Accounting|
|Ana Maria Tari||Research Director|
|Douglas P. Morris||Secretary & Non-Independent Director|
|Suzanne Kennedy||Director-Corporate Development|